TY - JOUR
AU - Gonzalez Dorta, Hector
AU - Verbeeck, Johan
AU - Crevecoeur, Jonas
AU - Loedy, Neilshan
AU - Cohet, Catherine
AU - Willem, Lander
AU - Molenberghs, Geert
AU - Hens, Niel
AU - Kurz, Xavier
AU - Quinten, Chantal
AU - Abrams, Steven
AU - Morales, Daniel R.
PY - 2025
DA - April
TI - Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study
JO - The Lancet Digital Health
VL - 7
IS - 5
DO - https://doi.org/10.1016/j.landig.2025.02.001
AB - BACKGROUND: Several COVID-19 vaccines have been licensed. To support the assessment of safety signals, we developed a toolkit to support COVID-19 vaccine monitoring and benefit-risk assessment. We aim to show the application of our toolkit in the EU using thrombosis with thrombocytopenia syndrome (TTS) associated with the Vaxzevria (AstraZeneca) vaccine as a use case.
PB - Elsevier
UR - https://discovery.dundee.ac.uk/en/publications/21219a20-9904-4039-a819-4d2a6ead3357
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
ER